Determining the efficacy of antiplatelet therapies for the individual: Lessons from clinical trials

Journal of Thrombosis and Thrombolysis

Volumn 26, Issue 1, 2008, Pages 8-13

  Steinhubl, Steven R ^a   Schneider, David J ^b   Berger, Peter B ^c   Becker, Richard C ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiplatelet therapy; Clinical trials; Drug development; Platelets

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LEFRADAFIBAN; LOTRAFIBAN; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; ORBOFIBAN; PLACEBO; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; SIBRAFIBAN; THIENOPYRIDINE DERIVATIVE; XEMILOFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; EX VIVO STUDY; HEART INFARCTION; HUMAN; INCIDENCE; INFLAMMATION; MONOTHERAPY; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK;

ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; INFLAMMATION; PATIENT SELECTION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; TREATMENT OUTCOME;

EID: 48449096863     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0160-3     Document Type: Article

References (37)

1. EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352:87-92
2. The ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 356:2037-2044
3. Kong DF, Hasselblad V, Harrington RA et al (2003) Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 92:651-655
4. Kereiakes DJ, Kleiman NS, Ferguson JJ et al (1998) Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial. Circulation 98:1268-1278
5. Ferguson JJ, Deedwania DC, Kereiakes DJ et al (1998) Sustained platelet glycoprotein IIb/IIIa blockade with oral orbofiban: Interim pharmacodynamic results of the SOAR study. J Am Coll Cardiol 31:185A
6. Cannon CP, McCabe CH, Borzak S et al (1998) Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Circulation 97:340-349
7. Giugliano RP, McCabe CH, Sequeira RF et al (2000) First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials. Am Heart J 140:81-93
8. Akkerhuis KM, Neuhaus KL, Wilcox RG et al (2000) Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J 21:2042-2055
9. Harrington RA, Armstrong PW, Graffagnino C et al (2000) Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 102:728-735
10. O'Neill WW, Serruys P, Knudtson M et al (2000) Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med 342:1316-1324
11. Cannon CP, McCabe CH, Wilcox RG et al (2000) Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 102:149-156
12. SYMPHONY Investigators (2000) Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. Lancet 355:337-345
13. 2nd SYMPHONY Investigators (2001) Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 103:1727-1733
14. Topol EJ, Easton D, Harrington RA et al (2003) Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108:399-406
15. Chew DP, Bhatt DL, Sapp S et al (2001) Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials. Circulation 103:201-206
16. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ (2000) Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 36:1514-1519
17. Holmes MB, Sobel BE, Cannon CP, Schneider DJ (2000) Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Am J Cardiol 85:491-493
18. Peter K, Schwarz M, Ylanne J et al (1998) Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIb-beta3) inhibitors. Blood 92:3240-3249
19. Quinn MJ, Plow EF, Topol EJ (2002) Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword? Circulation 106:379-385
20. Adderley SR, Fitzgerald DJ (2000) Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 275:5760-5766
21. OASIS-5 Investigators (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464-1476
22. Kastrati A, Mehilli J, Schuhlen H et al (2004) A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350:232-238
23. Kastrati A, Mehilli J, Neumann F-J et al (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 295:1531-1538
24. Limbruno U, Micheli A, De Carlo M et al (2003) Mechanical prevention of distal embolization during primary angioplasty: Safety, feasibility, and impact on myocardial reperfusion. Circulation 108:171-176
25. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ (2006) Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 118:361-369
26. Dalby M, Montalescot G, Bal dit Sollier C et al (2004) Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. J Am Coll Cardiol 43:162-168
27. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, the risk of cardiovascular disease in apparently healthy men (erratum in: N Engl J Med 1997; 337:356). N Engl J Med 336: 973-979
28. Feldman M, Jialal I, Devaraj S, Cryer B (2001) Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: A placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 37:2036-2041
29. Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH (2000) Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 9:37-41
30. Chew DP, Bhatt DL, Robbins MA et al (2001) Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 88:672-674
31. Steinhubl SR, Berger PB, Van Lente F et al (2004) Levels of hs-CRP prior to PCI predict long-term risk and the benefit of clopidogrel therapy: A CREDO sub-study. Circulation 110:III-382
32. Vivekananthan DP, Bhatt DL, Chew DP et al (2004) Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 94:358-360
33. Mehta SR, McQueen JM, Smieja M et al (2004) Baseline high-sensitivity C-reactive protein offers prognostic value in addition to contemporary risk stratification in non-ST-segment elevation acute coronary syndrome: results from the CURE inflammatory marker substudy. Circulation 110:III-498
34. Lenderink T, Boersma E, Heeschen C et al (2003) Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J 24:77-85
35. Ottervanger JP, Armstrong P, Barnathan ES et al (2003) Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS trial. Circulation 107:437-442
36. Lincoff AM, Kereiakes DJ, Mascelli MA et al (2001) Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 104:163-167
37. Gurbel PA, Yoho P, Bliden KP, Zaman K, Kreutz RP, Tantry US (2005) The effects of high vs. standard clopidogrel loading dose with and without eptifibatide on markers of inflammation: Results from the CLEAR PLATELETS study. Circulation 111:1153-1159